Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

71 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate.
Shack S, Miller A, Liu L, Prasanna P, Thibault A, Samid D. Shack S, et al. Among authors: thibault a. Clin Cancer Res. 1996 May;2(5):865-72. Clin Cancer Res. 1996. PMID: 9816242
Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.
Hultberg A, Morello V, Huyghe L, De Jonge N, Blanchetot C, Hanssens V, De Boeck G, Silence K, Festjens E, Heukers R, Roux B, Lamballe F, Ginestier C, Charafe-Jauffret E, Maina F, Brouckaert P, Saunders M, Thibault A, Dreier T, de Haard H, Michieli P. Hultberg A, et al. Among authors: thibault a. Cancer Res. 2015 Aug 15;75(16):3373-83. doi: 10.1158/0008-5472.CAN-15-0356. Epub 2015 Jul 3. Cancer Res. 2015. PMID: 26141862 Free article.
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE. Thibault A, et al. Clin Cancer Res. 1996 Mar;2(3):483-91. Clin Cancer Res. 1996. PMID: 9816194 Clinical Trial.
Peroxisome proliferator-activated receptor gamma as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity.
Samid D, Wells M, Greene ME, Shen W, Palmer CN, Thibault A. Samid D, et al. Among authors: thibault a. Clin Cancer Res. 2000 Mar;6(3):933-41. Clin Cancer Res. 2000. PMID: 10741718
Phenylbutyrate induces cell differentiation and modulates Epstein-Barr virus gene expression in Burkitt's lymphoma cells.
Bar-Ner M, Thibault A, Tsokos M, Magrath IT, Samid D. Bar-Ner M, et al. Among authors: thibault a. Clin Cancer Res. 1999 Jun;5(6):1509-16. Clin Cancer Res. 1999. PMID: 10389940
Modulation of radiation response of human tumour cells by the differentiation inducers, phenylacetate and phenylbutyrate.
Miller AC, Whittaker T, Thibault A, Samid D. Miller AC, et al. Among authors: thibault a. Int J Radiat Biol. 1997 Aug;72(2):211-8. doi: 10.1080/095530097143437. Int J Radiat Biol. 1997. PMID: 9269314
Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate.
Ram Z, Samid D, Walbridge S, Oshiro EM, Viola JJ, Tao-Cheng JH, Shack S, Thibault A, Myers CE, Oldfield EH. Ram Z, et al. Among authors: thibault a. Cancer Res. 1994 Jun 1;54(11):2923-7. Cancer Res. 1994. PMID: 8187079
Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells.
Prasanna P, Thibault A, Liu L, Samid D. Prasanna P, et al. Among authors: thibault a. J Neurochem. 1996 Feb;66(2):710-6. doi: 10.1046/j.1471-4159.1996.66020710.x. J Neurochem. 1996. PMID: 8592143
Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine.
Piscitelli SC, Thibault A, Figg WD, Tompkins A, Headlee D, Lieberman R, Samid D, Myers CE. Piscitelli SC, et al. Among authors: thibault a. J Clin Pharmacol. 1995 Apr;35(4):368-73. doi: 10.1002/j.1552-4604.1995.tb04075.x. J Clin Pharmacol. 1995. PMID: 7650225 Clinical Trial.
Phase I study of phenylacetate administered twice daily to patients with cancer.
Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE. Thibault A, et al. Cancer. 1995 Jun 15;75(12):2932-8. doi: 10.1002/1097-0142(19950615)75:12<2932::aid-cncr2820751221>3.0.co;2-p. Cancer. 1995. PMID: 7773944 Clinical Trial.
71 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback